Polar Capital Holdings Plc Cuts Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Polar Capital Holdings Plc lowered its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 21.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 56,249 shares of the biopharmaceutical company’s stock after selling 15,546 shares during the period. Polar Capital Holdings Plc owned about 0.05% of Regeneron Pharmaceuticals worth $40,068,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also made changes to their positions in REGN. Rakuten Securities Inc. lifted its stake in Regeneron Pharmaceuticals by 62.5% in the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 15 shares during the last quarter. OFI Invest Asset Management purchased a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth $28,000. Avalon Trust Co purchased a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth $36,000. Crowley Wealth Management Inc. acquired a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth $36,000. Finally, Private Wealth Management Group LLC increased its holdings in Regeneron Pharmaceuticals by 260.0% in the fourth quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company’s stock valued at $38,000 after buying an additional 39 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

REGN opened at $571.36 on Thursday. Regeneron Pharmaceuticals, Inc. has a twelve month low of $520.50 and a twelve month high of $1,211.20. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The firm has a market cap of $62.46 billion, a price-to-earnings ratio of 14.93, a PEG ratio of 2.34 and a beta of 0.43. The company has a fifty day simple moving average of $605.64 and a 200 day simple moving average of $689.30.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $8.83 by ($0.61). The business had revenue of $3.03 billion for the quarter, compared to analysts’ expectations of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm’s revenue was down 3.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $9.55 earnings per share. Equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th will be paid a dividend of $0.88 per share. The ex-dividend date is Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.62%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 8.96%.

Wall Street Analyst Weigh In

REGN has been the topic of a number of recent analyst reports. TD Cowen dropped their price objective on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating on the stock in a report on Tuesday, February 4th. BMO Capital Markets cut their price objective on shares of Regeneron Pharmaceuticals from $865.00 to $800.00 and set an “outperform” rating on the stock in a report on Wednesday, April 30th. Leerink Partnrs upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 5th. JPMorgan Chase & Co. decreased their price objective on shares of Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an “overweight” rating for the company in a research note on Monday, March 31st. Finally, Canaccord Genuity Group raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Tuesday, April 22nd. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, nineteen have issued a buy rating and three have issued a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $890.60.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.